Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study
This is a temporary file and hence do not link it from a website, instead link the URL of this page if you wish to link the PDF file.
To read this article you will require Adobe© Acrobat Reader, if you do not have this installed you can download it from here
Support open access
Subscribe for print copies